GSK3β inhibition and canonical Wnt signaling in mice hearts after myocardial ischemic damage by Badimon, Lina et al.
RESEARCH ARTICLE
GSK3β inhibition and canonical Wnt signaling
in mice hearts after myocardial ischemic
damage




1 Cardiovascular Program ICCC, Institut de Recerca de l’-Hospital de la Santa Creu i Sant Pau, Barcelona,





Myocardial infarction induces myocardial injury and tissue damage. During myocardial
infarction strong cellular response is initiated to salvage the damaged tissues. This
response is associated with the induction of different signaling pathways. Of these, the
canonical Wnt signaling is increasingly important for its prosurvival cellular role, making it a
good candidate for the search of new molecular targets to develop therapies to prevent
heart failure in infarcted patients.
Methods
Herein we report that GSK3β regulates the canonical Wnt signaling in C57Bl6 mice hearts.
GSK3β is a canonical Wnt pathway inhibitor. Using GSK3β inhibitors and inducing myocar-
dial injury (MI) in Lrp5-/- mice model we show that GSK3β phosphorylation levels regulate
downstream canonical Wnt pathway genes in the ischemic heart. In the setting of MI, myo-
cardial damage assessment usually correlates with functional and clinical outcomes. There-
fore, we measured myocardial injury size in Wt and Lrp5-/- mice in the presence and
absence of two different GSK3 inhibitors prior to MI. Myocardial injury was independent of
GSK3 inhibitor treatments and GSK3β expression levels.
Results
These studies support a central role for GSK3β in the activation of the canonical Wnt path-
way in the Wt heart. Although LRP5 is protective against myocardial injury, GSK3β expres-
sion levels do not regulate heart damage.
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Introduction
Acute myocardial infarction leads to acute cardiac ischemic injury. Myocardial infarction usu-
ally initiates with complete coronary artery occlusion because of the rupture of an atheroscle-
rotic plaque and the subsequent thrombotic process [1]. The extent of the cardiac injury
depends on the duration and location of the obstruction of the blood flow. Indeed, cardiomyo-
cytes in the cardiac tissue downstream from the blocked vessels can be killed within minutes
causing a massive and immediate inflammatory response that will clear the injured tissue. This
response will promote the formation of a sparse cellular tissue that will be filled in by different
cellular processes that include infiltration of myofibroblasts, which will deposit collagen and
other extracellular matrix proteins, and activation and proliferation of endothelial cells [2]. In
an attempt to restore blood supply, new vessels will be formed in a process named angiogene-
sis. Approximately a week after the initial ischemic assault a scar will form in the cardiac tissue.
The low regenerative capacity of the heart coupled to the extensive systemic response to pre-
serve ventricular integrity will eventually cause a permanent loss of cardiac tissue that will lead
to ventricular remodeling and heart failure. Sometimes, efficient and synchronous heart con-
traction is compromised by excessive scar formation that acts as a barrier to allow a correct
electromechanical signaling between the healthy regions of the heart. A better understanding
of the cellular and molecular mechanisms involved in cardiac repair could help design strate-
gies to delay the onset of heart failure in infarcted patients.
During embryonic development Wnt signaling, an intracellular pathway that regulates ver-
tebrate cardiomyocyte differentiation[3], can act through three different mechanisms: a β-cate-
nin dependent pathway called canonical Wnt pathway, and two β-catenin independent
pathways called noncanonical Wnt pathways [3,4]. The canonical Wnt pathway is activated
when an extracellular Wnt ligand binds to a seven-pass transmembrane Frizzled (Fz) receptor
and its co-receptor low-density lipoprotein receptor related protein 5 (LRP5) or LRP6. Extra-
cellular lipids have also been shown to activate canonical Wnt signaling [5]. Ligand binding to
the Wnt receptors induces the recruitment of the cytoplasmic scaffolding protein Dishevelled
(Dvl) resulting in LRP5 phosphorylation and the recruitment of the cytoplasmic axin complex
to the plasma membrane. The axin complex is composed of the scaffolding protein Axin, the
tumor suppressor protein Adenomatous Polyposis Coli (APC), casein kinase 1 (CK1), and gly-
cogen synthase kinase 3β (GSK3β). After the destruction of the axin complex, β-catenin is sta-
bilized and accumulates in the cytoplasm until it eventually translocates to the nucleus to form
complexes with the DNA-bound T Cell Factor/Lymphoid Enhancer Factor (TCF/LEF) family
of transcription factors activating Wnt target gene expression. In the absence of a Wnt ligand,
cytoplasmic β-catenin is constantly degraded by the axin complex. Indeed, GSK3β sequentially
phosphorylates the amino terminal region of β-catenin, resulting in β-catenin recognition by
an E3 ubiquitin ligase subunit, β-Trcp, and subsequent β-catenin ubiquitination and proteaso-
mal degradation [6]. This continual elimination of β-catenin prevents β-catenin from reaching
the nucleus, and Wnt target genes are thereby repressed. Several known target genes regulated
by the canonical Wnt signalling pathway are: cyclo-oxygenase-2[7], c-jun [8], vascular endo-
thelial growth factor (VEGF) [9], matrix metalloproteinase 7 (MMP7) [10], osteopontin
(OPN) [11] and bone morphogenetic protein 2 (BMP2) [12].
We have recently described the prosurvival function of the canonical Wnt pathway in vascu-
lar cells of atherosclerotic lesions [5, 13–15] and in myocardial injury (MI) [16]. Expression of
several Wnt pathway proteins such as β-catenin and Dvl are increased in the damaged tissue
after experimental myocardial infarction-induction [17–20]. However there is an ongoing con-
troversy on the effects of Wnt signaling activation on cardiac recovery after myocardial damage.
Indeed, the overexpression of two Wnt signaling antagonists, secreted Fz-related protein 1
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(sFRP1) and sFRP2 was reported to reduce infarct size and improve cardiac function, suggest-
ing that blocking Wnt signaling is cardioprotective in mice [17, 21, 22]. In apparent contradic-
tion, sFRP2 deficient mice subjected to ischemic damage show smaller infarcts and improved
cardiac function [20]. Furthermore, the transfer of β-catenin (with a constitutively active adeno-
virus) in a rat myocardial infarction model induced a reduction in infarct size [23]. We have
previously evidenced that mice lacking Lrp5 (Lrp5-/- mice) show more myocardial damage than
Wt mice [16] suggesting that canonical Wnt signaling activation is cardioprotective. A possible
explanation for these apparent contradictory results is that experiments were performed in dif-
ferent animal models with different myocardial injury-induction times and used different
parameters to analyze Wnt pathway modulation. A major regulator for the canonical Wnt path-
way is GSK3β. GSK3β is an evolutionary conserved, ubiquitous serine/threonine kinase that
participates in several signaling pathways [24–26]. To date, numerous studies have indicated
that GSK3β acts as a downstream regulator that determines the outcome of several prominent
pathways following stimuli such as Wnt signaling, phosphatidylinositol 3-kinase, and neuro-
trophic pathways. The diverse functions of GSK3β include the regulation of circadian rhythms
[27] and cell structure, and survival [26, 28]. Deregulation of GSK3β has been involved in diabe-
tes, schizophrenia, Alzheimer disease and cancer [26, 29]. However, the precise signaling mech-
anisms in which GSK3β is involved are not well understood and it is an area of active research.
GSK3β is unique because it is constitutively active in cells in resting conditions where it is pri-
marily regulated by inhibition of its activity. GSK3β activity is positively regulated by phosphor-
ylation of Tyr216 and negatively regulated by N-terminal phosphorylation of Ser9 [25]. Indeed,
increased phophorylation in Tyr216 of GSK3β in neuronal cells correlated with an increase in
GSK3β activity [30, 31]. Furthermore inhibition of GSK3β Tyr216 phosphorylation decreased
the survival and/or proliferation of different types of cancer, both in vitro and in vivo [32, 33].
To further understand the role of the canonical Wnt pathway in myocardial injury we have
investigated the role of GSK3β in the heart of Lrp5-/- and wild type mice.
Materials and methods
Nomenclature
Mice genes are written in italics (Lrp5) and mice proteins in straight capital block letters
(LRP5) in accordance with the guidelines from the “International Committee on Standardized
Genetic Nomenclature for Mice and the Rat Genome”, 2010.
Animals and experimental design
All procedures were approved by the Institutional Animal Care and Use Committee
(CEEA-ICCC) and approved by local government animal experimentation with number 5422
on 10/05/2010. The study protocols for mice were approved by the institutional animal care and
use committee (ICCC051⁄5422) and authorized by the local government commission. All animal
procedures follow the guidelines from Directive 2010/63/EU of the European Parliament and
the “Position of the American Heart Association on Research Animals use” (November 11,
1984). Therefore all animal studies have been approved by the ethics committee of our Hospital
and have been performed in accordance with the ethical standards laid down in the 1964 Decla-
ration of Helsinki and its later amendments. At the Hospital de la Santa Creu i Sant Pau we are
committed to the “3Rs” principle and hence used the minimum of animals required to achieve
statistical significance. Lrp5-/- mice, a kind gift from Dr. Bart Williams [34–36], were maintained
in a C57BL/6 background. Mice were housed in cages under controlled temperature (21±2˚C)
on a 12h light/ dark cycle with food and water ad libitum. Homozygous wild type C57BL/6 mice
(Wt) and Lrp5-/- C57BL/6 mice (Lrp5-/-) were used in this study. The presence of Lrp5 alleles
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was assessed by PCR amplification from DNA extracted from tail biopsies in wild type, hetero-
zygous and homozygous littermates. Primers used were S17 (GGC TCG GAG GAC AGA CCT
GAG), S23 (CTG TCA GTG CCT GTA TCT GTC C) and IRES31 (AGG GGC GGA ATT
CGA TAG CT). Lrp5-/- and Wt mice were fed a normal chow diet (NC, Tekland diet, Harland
Labs) for 18 weeks when experiments were performed. At sacrifice, cardiac puncture was per-
formed in mice under terminal anesthesia (1mg/kg Medetomidine and 75mg/kg Ketamine, ip).
Mice acute myocardial ischemic damage
For experimental myocardial injury (MI)-induction male mice were analgesized (buprenor-
phine 0.1mg/kg, i.p.), anesthetized with a mixture of ketamine (75mg/kg, i.p.) and medetomi-
dine (1mg/kg, i.p.), intubated and mechanically ventilated (100% O2, 90 breaths/min; SAR-830;
CWE Inc.). The heart was exposed through a medial incision of the chest and the left anterior
descending (LAD) coronary artery was permanently occluded at the site of its emergence from
under the left atrium with an intramural stitch (7–0 silk suture) for 60 minutes. Ischemia was
confirmed by immediate bleach of the myocardium and momentary elevation of the ST wave in
the ECG. Heart rate, ECG and body temperature were recorded throughout the experimental
procedure using a Biosonic pad (Bioscan). At the end of the MI induction hearts were extracted,
immersed in fixative solution (4% paraformaldehyde), embedded in OCT, cut into 5 μm thick
serial sections and placed on poly-L-lysine coated slides. Hematoxylin and eosin and Masson’s
Trichrome staining was performed to visualize tissue structure and calculate the damaged area
in the left ventricle and interventricular septum. Images were captured by Leica MZ95 stereo-
microscope and digitized by Retiga 1300i Fast camera. A section every five cuts was analyzed
and myocardial injury was measured by Image J software as the percentage of the damaged area
in relation to the total left ventricle. In order to reduce variability, myocardial injury assessments
were all performed by the same investigator and blindly to mice genotype.
One group of Wt and Lrp5-/- mice was treated with CHIR99021 (15mg/kg, i.p.; Selleck-
chem; 90 minutes half life) a highly selective inhibitor of GSK3 1 hour prior to MI induction.
Another group of Wt mice was treated with SB415286 (10mg/kg i.p; Sigma Aldrich; 20 hours
half life), another GSK3 inhibitor with a longer half life than CHIR99021, 24h and 2h prior MI
induction. After 60 minutes of MI-induction mice were euthanized, hearts were separated into
ischemic and non-ischemic regions and frozen in liquid nitrogen. Another set of hearts were
fixed in PFA, stained with haematoxylin-eosin and Masson Trichromic and myocardial dam-
age analyses were performed. Sham-operated mice, which underwent the same surgical proce-
dure without arterial ligation, served as controls. The organs were harvested for further
analysis. Additionally, after MI induction, two groups: Wt and Wt+SB415286 mice underwent
90 minutes of reperfusion when the hearts were extracted, fixed in PFA or frozen in liquid
nitrogen. A minimum of 6 mice/group was performed.
The study groups are summarized below:
Wt and Lrp5-/- mice: 1h MI.
Wt and Lrp5-/- mice: 1h CHIR99021+ 1h MI.
Wt mice: 24h SB415286 (two injections at 24h and 2 h prior MI) + 1h MI.
Wt mice: 1h MI+ 90 min reperfusion.
Wt mice: 24h SB415286 (two injections at 24h and 2 h prior MI) + 1h MI+ 90 min
reperfusion.
Canonical Wnt and myocardial injury
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Real time RT-PCR
Ischemic and non ischemic regions of hearts of the different mice study groups were frozen in
liquid nitrogen for gene and protein analyses. Myocardial RNA was isolated with Trizol
Reagent (Invitrogen) (n = 5–7 mice/group). Concentration was determined with a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA) and
purity was checked by the A260/A280 ratio (ratios between 1.8 and 2.1 were considered
acceptable). cDNA was synthesized from 1 μg RNA with cDNA Reverse transcription kit (Qia-
gen). The resulting cDNA samples were amplified with a RT-PCR thermal cycler (Applied Bio-
systems 7900HT) and the following specific probes from Applied Biosystems: Lrp5
(Mm01227476_m1), Lef1 (Mm00550265_m1), β-catenin (Mm00483039_m1), Vegf
(Mm00437306_m1) and Gsk3β (Mm00444911_m1). Results were normalized with 18S probe
from Applied Biosystems.
Western blot
Sample extracts (30μg protein) were resolved by SDS-PAGE and transferred to nitrocellulose
membranes, blocked with 5% skim milk and probed for monoclonal GSK3β and LRP5
(Abcam), LEF1 (Millipore)or polyclonal pY216 GSK3β, VEGF (Abcam) primary antibodies at
a concentration of 1μg/ml. Membranes were then washed and blotted with the appropriate
secondary antibody (Dako). Band densities were determined with the ChemiDoc XRS system
(Bio-Rad) in chemiluminescence detection modus and Quantity-One software (Bio-Rad).
Normalization was performed against β-ACTIN.
Statistical analysis
The Shapiro-Wilk test was applied to verify the normal distribution of data. Intergroup com-
parisons were performed by using unpaired Student t tests or analysis of variance tests fol-
lowed by Fisher protected least significant difference as post hoc analysis. A p value of<0.05
was considered significant, and results are reported as mean ± SEM. All the experiments were
performed at least three times. All statistical analyses were conducted using Statview and R
version 3.3.0 software (R Foundation for Statistical Computing).
Results
p-GSK3β levels in hearts of Wt and Lrp5-/- mice
To evaluate the response of Wnt pathway components to myocardial ischemic injury, we per-
manently occluded the left anterior descending (LAD) coronary artery of male C57BL/6J Wild
Type (Wt) and male Lrp5-/- mice for 1hour and sacrificed the animals. Another set of Wt and
Lrp5-/- male mice were administered CHIR99021 (15mg/kg, i.p.), 1 hour prior to LAD occlu-
sion and sacrificed. CHIR99021 is a selective small molecule GSK3 inhibitor that activates
Wnt signaling.
Phosphorylated GSK3β (p-GSK3β, Tyr216) protein levels were higher in ischemic regions of
hearts from Lrp5-/- mice than in those from Wt mice (Fig 1A). Total GSK3β protein levels were
also increased in the myocardium of Lrp5-/- mice compared to Wt mice. We performed phos-
phorylated GSK3β/Total- GSK3β ratios to analyze total myocardial content of activated
GSK3β and found no differences between genotypes (Fig 1A). CHIR99021 treatment signifi-
cantly reduced p-GSK3β protein levels in Lrp5-/- mice but not in Wt mice. CHIR99021 treat-
ment reduced p-GSK3β to the same level in both genotypes. Induction of myocardial injury
(MI) causes a highly significant increase of p-GSK3β protein levels in Wt and Lrp5-/- mice,
strongly suggesting that injury affects the canonical Wnt pathway (Fig 1B). Treatment with
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CHIR99021 before occlusion significantly reduced p-GSK3β levels in both genotypes (Fig 1C)
further demonstrating efficacy of CHIR99021 treatments. Indeed, levels of p-GSK3β protein
Fig 1. p-GSK3β levels in hearts of Wt and Lrp5-/- mice. Representative WB of phosphorylated GSK3β at Tyr216, total GSK3β protein and β-ACTIN expression levels in
ischemic hearts of Wt and Lrp5-/- mice (A) with or without 15 mg/kg i.p. CHIR990021 treatments (B) after myocardial injury (MI)-induction and (C) after CHIR99021
treatments and MI induction. Bar graphs showing the quantification of the WB bands intensity p-GSK3β/T- GSK3β protein. (D) GSK3β mRNA expression levels in hearts
of Wt and Lrp5-/- mice with or without CHIR990021 treatments and MI induction. (E) Myocardial damage measurements of Wt and Lrp5-/- mice after MI in the presence
and absence of CHIR99021. 6–10 male mice /condition �p<0,05; ���p<0,005, ns: non significant.
https://doi.org/10.1371/journal.pone.0218098.g001
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were significantly reduced after CHIR99021 treatments in damaged hearts leaving the canoni-
cal pathway open for activation and for β-catenin interaction with specific transcription
factors.
We then assessed the expression GSK3β using real-time quantitative reverse transcriptase
(RT)-PCR analysis. Results followed a similar pattern as protein expression indicating that
CHIR99021 treatments are effective in inhibiting GSK3β myocardial gene expression in both
mice genotypes (Fig 1D).
Myocardial injury in Wt and Lrp5-/- mice after CHIR99021 treatments
Myocardial damage, measured blindly as previously done in [16], was significantly larger in
Lrp5-/- mice than in Wt mice. However myocardial damage assessment was independent of
CHIR99021 treatments and GSK3β levels. Indeed, reduction of GSK3β protein or gene levels
did not have any effect on myocardial injury size.
Wnt signaling in hearts of mice
We then analyzed components and targets of the canonical Wnt signaling pathway in the ische-
mic myocardium of Wt and Lrp5-/- mice. In Wt mice, Lrp5 mRNA and protein expression levels
were downregulated immediately after MI-induction compared to sham animals (Fig 2A).
However, expression of genes and proteins downstream GSK3β including β-catenin, Lef1 and
Vegf maintained similar expression in sham and MI induced Wt and Lrp5-/- mice (Fig 2B–2D).
After CHIR99021 treatments βcatenin, Lef1 and Vegf gene and protein levels were increased in
MI Wt mice (Fig 2B–2D). Interestingly, CHIR99021 treatments induced an increase in Lrp5
mRNA levels after MI although its target is downstream the receptor. Similarly to Wt mice, in
Lrp5-/- mice, downstream Wnt signaling proteins were not induced in sham or MI-mice (Fig
2B–2D). There were no significant differences in gene expression levels between the myocar-
dium of sham operated mice and non ischemic regions of MI-induced mice (S1 Fig).
Myocardial damage in Wt mice after ischemia reperfusion
We then performed experiments aimed to determine the contribution of myocardial reperfu-
sion to the modulation of the Wnt pathway. To this end we induced 60 minutes MI to Wt
mice followed by 90 minutes reperfusion when animals were sacrificed (MI+Rep). Again, Wt
mice which underwent the same surgical procedure without arterial ligation, served as controls
(sham). A set of animals were treated 24h and 2h prior to MI induction with SB415286, a
potent, selective and cell permeable GSK3 inhibitor with approximately 20 hours of half life
([37] CHIR99021 has a half life of approximately 90 min).
Results showed decreased p-GSK3β protein levels after SB415286 treatments in sham and
MI-induced Wt animals. p-GSK3β (Tyr216)/T-GSK3β ratios are also shown (Fig 3A). GSK3β
mRNA expression levels in Wt mice previously treated with SB415286 were also reduced as
compared with untreated animals (Sham: 60.8% and MI: 51%; Fig 3B). However no reduction in
p-GSK3β expression levels could be observed in the myocardium of reperfused mice (Fig 3A).
Measurements of myocardial injury show a 20% increase in Wt mice MI+Rep as compared
to mice without reperfusion (Fig 3C). SB415286 treatments only reduced myocardial damage
by 8% after reperfusion (Fig 3C).
Wnt genes expression in hearts of Wt mice after reperfusion
Analyses of Wnt signaling genes after MI in hearts of Wt mice show decreased Lrp5and Vegf
gene and protein expression after MI-induction compared with sham operated animals (Fig
Canonical Wnt and myocardial injury
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Fig 2. Canonical Wnt signaling proteins expression in hearts of Wt and Lrp5-/- mice. mRNA expression levels and representative images of western blots
showing protein expression levels of (A) Lrp5, (B) β-catenin, (C) Lef1 and (D) Vegf in hearts of Wt and Lrp5-/- mice. 6–10 male mice /condition �p<0,05;
��p<0,01; ���p<0,005; ns: non significant.
https://doi.org/10.1371/journal.pone.0218098.g002
Canonical Wnt and myocardial injury
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4A and 4D). Wt mice with ischemia-reperfusion treatments showed reduced canonical Wnt
gene expression levels compared to non-reperfused MI-mice in Lrp5 (19%), β-catenin (51%),
Lef1 (70%) and Vegf (60%; Fig 4A–4D). SB415286 treatments prior to MI in Wt mice increased
the expression levels of the canonical Wnt pathway genes and proteins tested (Fig 4A–4D).
However, SB415286 treatments in reperfused mice did not induce modifications in the expres-
sion levels of Lrp5, β-catenin, Lef1 or Vegf as compared to MI+Rep mice.
Discussion
We have extensively studied the role of LRP5 and the canonical Wnt pathway in Lrp5-/- mice.
We have shown that LRP5 is involved in several cellular processes including inflammation,
monocyte differentiation, dislypidemia and atherosclerosis progression [5, 14, 15, 38]. Activa-
tion of canonical Wnt signaling pathway by extracellular Wnt ligands or lipids is inhibited in
Fig 3. p-GSK3β in ischemic hearts of Wt and Lrp5-/- mice. (A) Protein levels of phosphorylated and total GSK3β in hearts of Wt mice with or without 10mg/kg i.p.
SB415286. p-GSK3β/T-GSK3β ratio of WB band intensities normalized with β-ACTIN. (B) mRNA expression (C) Myocardial damage assessment and representative
images of Wt mice after MI and MI+Rep in the presence and absence of SB415286. 6–10 mice /condition �p<0,05; ��p<0,01; ���p<0,005.
https://doi.org/10.1371/journal.pone.0218098.g003
Canonical Wnt and myocardial injury
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Fig 4. Canonical Wnt signaling protein expression in hearts of Wt mice after reperfusion. mRNA expression levels and representative images of protein expression
levels of (A) Lrp5, (B) β-catenin, (C) Lef1 and (D) Vegf in hearts of Wt mice after 90 minutes reperfusion in the presence or absence of SB415286. 6–10 mice /condition
�p<0,05; ��p<0,01; ���p<0,005; ns = non significant.
https://doi.org/10.1371/journal.pone.0218098.g004
Canonical Wnt and myocardial injury
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aortas of Lrp5-/- mice but not in Wt mice [13]. Similarly, activation of the Wnt pathway is also
abolished in circulating white cells of Lrp5-/- mice [14]. Here we show that Lrp5-/- mice have
increased myocardial GSK3β transcription and protein levels opening the possibility that the
previously observed inhibition of the canonical Wnt pathway in aortas and circulating white
cells of Lrp5-/- mice may be due to synergic effects of the lack of LRP5 and the increased
GSK3β levels. However, further work is needed to confirm this hypothesis.
Mice results show that phosphorylated GSK3β myocardial levels regulate Wnt pathway acti-
vation in Wt mice. Indeed, MI-induced Wt and Lrp5-/- mice show high p-GSK3β levels with-
out upregulation of canonical Wnt genes. The administration in Wt mice of CHIR99021, a
canonical Wnt pathway activator, downregulated myocardial p-GSK3β levels and the expres-
sion of canonical Wnt genes increased (Fig 5). Several canonical Wnt pathway proteins and
targets have been previously shown to be modulated in short periods of time. Indeed, β-cate-
nin was increased as soon as 30 minutes after estradiol treatment in neuroblastoma cell lines
[39], and VEGF protein expression in rat muscular fibres was significantly increased after only
90 minutes of exercise [40]. Other proteins that activate other signalling pathways are also reg-
ulated in short periods of time. Indeed, induction of c-fos mRNA was observed in mice ische-
mic cortex after 60 minutes of ischemia [41], and JAK 3 protein expression was significantly
increased following 30 minutes of IL-2 stimulation and was sustained after 60 minutes in
murine podocytes [42].
Long term GSK3β inhibition, induced by SB415286 administration downregulated p-
GSK3β expression in the heart of Wt sham and MI-induced mice. Similar to CHIR99021
Fig 5. Schematic drawing of canonical Wnt signaling and GSK3β inhibitors. (A) Inactive canonical Wnt signaling: β-CATENIN is recruited into a cytoplasmic complex
with AXIN, CASEIN KINASE 1 (CK1), ADENOMATOUS POLIPOSIS COLI (APC) and GSK3β that phosphorilates β-CATENIN targeting it for proteasomal
degradation. (B) Protein levels of canonical Wnt proteins in hearts of Wt mice Sham vs MI or MI vs MI+SB415. (C) Protein expression levels of canonical Wnt proteins in
hearts of Wt mice Sham vs MI+Rep or MI+Rep vs MI+SB415+Rep. (D) GSK3β inhibitors (CHIR99021 and SB415286) induce canonical Wnt signaling activation. β-
CATENIN accumulates in the cytoplasm, translocates to the nucleus, binds to lymphocyte enhancer binding factor 1 (LEF1) family and initiates Wnt genes transcription.
https://doi.org/10.1371/journal.pone.0218098.g005
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administration in Wt mice, SB415286 treatments induced an increase in Wnt signaling gene
expression. Indeed, sham operated mice did not show Wnt gene expression variation before
and after CHIR99021 or SB415286 treatments suggesting that the Wnt pathway is maintained
in an inactive state until an injury occurs. This is sustained by our previous results where
human macrophages in control conditions show an inactive Wnt signaling [5]. However, after
LDL treatments, and upon Wnt pathway activation, β-CATENIN is translocated to the nucleus
where it initiates canonical Wnt signaling genes transcription [5]. Unexpectedly,
SB415286-treated Wt mice that had reperfusion after MI did not show reduced myocardial p-
GSK3β levels. Accordingly Wnt signaling genes variations are minimal. These results further
support that p-GSK3β levels regulate myocardial Wnt signaling in Wt mice and suggest that
reperfusion inhibits GSK3β protein downregulation.
Previous studies on GSK3 inhibition on ischemia/reperfusion injury in Wt animals
reported protective effects of GSK3 inhibitors in rabbits and rat hearts, in isolated perfused
hearts and in isolated cardiomyocytes [43–47]. However, GSK3 inhibitors have also been
reported not to induce protection in isolated perfused C57BL/6 mouse hearts using a global
model of ischemia in a Langendorff heart [48]. Our results support a reduction in myocardial
damage after the administration of GSK3 inhibitors in Wt ischemia reperfused mice. However,
this does not correlate with reduced GSK3β protein levels nor with the triggering of canonical
Wnt activation.
Currently there is an unfinished debate on the effects of the activation of the canonical Wnt
signaling in the heart after myocardial damage [16, 17, 20, 23]. Indeed, transgenic mice that
express a constitutively active form of GSK3β show diminished hypertrophy of cardiomyo-
cytes in response to pressure overload [49]. Also, inhibition of GSK3β in perfused rat hearts
after ischemic preconditioning resulted in the accumulation of β-catenin in the cytosol and
nucleus [50]. Furthermore overexpression of sFRP1, an antagonist of the Wnt pathway, in
mice with ischemic preconditioning after MI induced the activation of GSK3β [18]. However,
permanent coronary artery ligation with no reperfusion in mice that overexpress sFRP1
showed reduced GSK3β activity [17]. Therefore, although the modulation of upstream signals
of GSK3β in myocardial-ischemia has been investigated previously, myocardial ischemia mod-
els were different, and none of these studies inhibited LRP5 directly. In our in vivo non reper-
fused mice model we treated mice with an activator of the canonical Wnt pathway for 24h
(long term) or 1h (short term) prior to MI induction and observed an increase in Wnt signal-
ing gene expression. However, after 90 minutes reperfusion there was no reduction in the
phosphorylation status of GSK3β and canonical Wnt signaling genes variations were minimal
suggesting that reperfusion inhibits GSK3β protein downregulation. Our results show that
GSK3β expression does not correlate with myocardial injury size in Wt mice. Indeed a reduc-
tion in p-GSK3β expression levels in mice that followed CHIR99021 or SB415286 treatments
prior to MI did not induce reduced myocardial damage. Furthermore, Wt mice treated with
CHIR99021 prior to MI had increased myocardial damage than those untreated. Similarly,
Lrp5-/- mice after CHIR99021 treatments did not show reduced myocardial injury size.
Therefore, we conclude that GSK3β plays a central role in the activation of the canonical
Wnt pathway in the heart in Wt mice. However, GSK3β expression levels do not predict the
outcome of myocardial damage.
Supporting information
S1 Fig. Canonical Wnt signaling genes expression in ischemic and non ischemic regions of
Wt and Lrp5-/- mice. mRNA expression levels of (A) Lrp5, (B) β-catenin, (C) Lef1 and (D)
Vegf in ischemic (I) and non ischemic (NI) regions of myocardium of Wt and Lrp5-/- mice.
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